Resting-state fMRI as a biomarker for Alzheimer's disease?
Functional Imaging in Neuropsychiatric Disorders Lab, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, 780 Welch Road, Suite 105, Palo Alto, CA 94304, USA
Alzheimer's Research & Therapy 2012, 4:8 doi:10.1186/alzrt106
See related review by Vemuri et al., http://alzres.com/content/4/1/2Published: 15 March 2012
Previous work indicates that resting-state functional magnetic resonance imaging (fMRI) is sensitive to functional brain changes related to Alzheimer's disease (AD) pathology across the clinical spectrum. Cross-sectional studies have found functional connectivity differences in the brain's default mode network in aging, mild cognitive impairment, and AD. In addition, two recent longitudinal studies have shown that functional connectivity changes track AD progression. This earlier work suggests that resting-state fMRI may be a promising biomarker for AD. However, some key issues still need to be addressed before resting-state fMRI can be successfully applied clinically. In a previous issue of Alzheimer's Research & Therapy, Vemuri and colleagues discuss the use of resting-state fMRI in the study of AD. In this commentary, I will highlight and expand upon some of their main conclusions.